Commentary on Idelalisib by Dr. Richard Furman Dr. Rick Furman of the CLL Society Scientific Advisory Board helps explain the recent warning about idelalisib and provides us... March 28, 2016Business, Finances, Insurance & RegulatoryBy Todd Dennison
Update on Idelalisib (Zydelig) Two weeks ago, Gilead provided the following statement: At Gilead, patient safety is our highest priority and we continuously monitor safety... March 25, 2016Business, Finances, Insurance & RegulatoryBy Todd Dennison
FDA Halts Six Idelalisib Combination Studies Six clinical trials exploring idelalisib (Zydelig) in combination with other therapies have been halted due to reports of an increased... March 16, 2016Business, Finances, Insurance & RegulatoryBy Todd Dennison
Imbruvica® (ibrutinib) Approved by U.S. FDA for the First-Line Treatment of Chronic Lymphocytic Leukemia March 4, 2016 - The U.S. Food and Drug Administration approved Imbruvica® (ibrutinib) as a first-line treatment for patients with... March 4, 2016Business, Finances, Insurance & RegulatoryBy Todd Dennison
Dealing with the Psychosocial Aspects of Cancer Dr. Scott Irwin is a psychiatrist who is the Director of Psychiatry and Psychosocial Services at the UCSD Moores Cancer... January 24, 2016News, SupportBy Todd Dennison
Participate in the 2016 Global Patient Survey The CLL Society is a member of the Lymphoma Coalition. Each year they field a Global Patient Survey to help... January 22, 2016NewsBy Todd Dennison
FDA Approves Maintenance Treatment with Ofatumumab in CLL On January 19, 2016, the U.S. Food and Drug Administration approved ofatumumab (Arzerra) for extended treatment of patients who are... January 22, 2016Business, Finances, Insurance & RegulatoryBy Todd Dennison
FDA Grants Priority Review for Venetoclax New Drug Application Jan 12, 2016. The U.S. Food and Drug Administration (FDA) has granted Priority Review for venetoclax for the treatment of... January 22, 2016Business, Finances, Insurance & RegulatoryBy Todd Dennison
LRF Interview with Dr. Bruce Cheson on Personalized Therapy in CLL Dr. Bruce Cheson from Georgetown University discusses the practical applications of personalized therapy in chronic lymphocytic leukemia (CLL): what is... January 14, 2016NewsBy Todd Dennison
Dr. Kay on Clinical Trials using Ibrutinib for Untreated CLL Patients Unless one is 17p deleted, the best and perhaps only way to get ibrutinib frontline to treat chronic lymphocytic leukemia... January 10, 2016NewsBy Todd Dennison
